Olema Pharmaceuticals News

Buy Rating Affirmed for Olema Pharmaceuticals on Strong Clinical Trial Data for Palazestrant and Ribociclib Combination

TipRanksMay 16 05:08

Buy Rating Justified by Promising Efficacy and Safety Profile of Olema Pharmaceuticals' Drug Combination in Clinical Studies

TipRanksMay 15 14:45

HC Wainwright & Co. Reiterates Buy on Olema Pharmaceuticals, Maintains $30 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and maintains $30 price target.

BenzingaMay 15 12:58

Promising Clinical Trial Results Bolster Buy Rating for Olema Pharmaceuticals

TipRanksMay 15 10:45

OPEN, BCRX and AWIN Among Pre-market Gainers

Seeking AlphaMay 15 08:25

Olema Pharmaceuticals Announces Promising Breast Cancer Trial Results

TipRanksMay 15 06:22

Olema Oncology Announces Interim Results From Phase 1b/2 Palazestrant Study, Says 85% Clinical Benefit Rate Observed To Date Across All CBR-Eligible Patients

Olema Oncology Announces Interim Results From Phase 1b/2 Palazestrant Study, Says 85% Clinical Benefit Rate Observed To Date Across All CBR-Eligible Patients

BenzingaMay 15 06:12

Olema Oncology Announces Promising New Data for Palazestrant in Combination With Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

Across 50 treated patients, palazestrant (OP-1250) in combination with ribociclib was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug exposure of either

GlobeNewswireMay 15 06:01

We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares

Simply Wall StMay 11 09:44

Olema Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Olema Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMay 9 14:41

HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Raises Price Target to $28

HC Wainwright & Co. analyst Emily Bodnar maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and raises the price target from $25 to $28.

BenzingaMay 9 14:31

Olema Pharmaceuticals Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 172.9% HC Wainwright & Co. $25 → $28 Maintains Buy 04/02/2024 133.92% Goldman Sachs → $24 Initi

BenzingaMay 9 14:30

Analysts Are Bullish on Top Healthcare Stocks: Olema Pharmaceuticals (OLMA), Arcus Biosciences (RCUS)

TipRanksMay 9 07:04

Buy Rating on Olema Pharmaceuticals Amid Promising Clinical Trials and Strong Financial Position

TipRanksMay 9 06:05

Buy Rating Affirmed on Olema Pharmaceuticals Amid Promising Breast Cancer Treatment Advances and Strategic Novartis Collaboration

TipRanksMay 8 17:45

Olema Pharmaceuticals Q1 EPS $(0.56) Misses $(0.51) Estimate

Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.51) by 9.8 percent. This is a 20 percent increase over losses of $

BenzingaMay 8 16:05

Olema Pharmaceuticals | 10-Q: Quarterly report

Futu NewsMay 8 15:23 · Announcements

Olema Pharmaceuticals Cash, Cash Equivalents and Marketable Securities as of March 31 Were $249M >OLMA

Olema Pharmaceuticals Cash, Cash Equivalents and Marketable Securities as of March 31 Were $249M >OLMA

Dow JonesMay 8 15:12

Olema Pharmaceuticals 1Q Loss/Shr 56c >OLMA

Olema Pharmaceuticals 1Q Loss/Shr 56c >OLMA

Dow JonesMay 8 15:11

Press Release: Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update -- Completed enrollment in 60-patient Phase 1b/2 clinical studies of palazestrant in combination wit

Dow JonesMay 8 15:02